(Q48882553)

16 February 2018

title

Neurotransmitters and CNS disease. Schizophrenia. (English)

1 reference

16 February 2018

0 references

1 reference

S H Snyder

1

1 reference

16 February 2018

language of work or name

English

0 references

publication date

1 October 1982

1 reference

16 February 2018

published in

The Lancet

1 reference

16 February 2018

volume

2

1 reference

16 February 2018

page(s)

970-974

1 reference

16 February 2018

issue

8305

1 reference

16 February 2018

A critical review of recent adoption, twin, and family studies of schizophrenia: behavioral genetics perspectives

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Cerebral ventricular size and cognitive impairment in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

The dementia of dementia praecox.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Structural Abnormalities in the Cerebral Cortex of Chronic Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Cerebral ventricular size and neuropsychological impairment in young chronic schizophrenics. Measurement by the standardized Luria-Nebraska Neuropsychological Battery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Computed tomography in schizophrenics and normal volunteers. I. Fluid volume

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Cerebral ventricular enlargement in young manic males. A controlled CT study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Behavioral precursors of schizophrenia spectrum. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Molecular pathology of schizophrenia: more than one disease process?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain, and its similarity to the "dopamine receptor".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Multiple receptors for dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Antipsychotic drug doses and neuroleptic/dopamine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Schizophrenic Symptoms Improve with Apomorphine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Behavioral effects of l-Dopa in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Special antagonism of amphetamine-induced abnormal behaviour. Inhibition of stereotyped activity with increase of some normal activities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Catecholamines in the brain as mediators of amphetamine psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Increased dopamine-receptor sensitivity in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Receptors, Neurotransmitters and Drug Responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Increased brain dopamine and dopamine receptors in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Plasma prolactin concentrations and psychopathology in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Norepinephrine in Chronic Paranoid Schizophrenia: Above-Normal Levels in Limbic Forebrain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Brain Norepinephrine and Dopamine in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Schizophrenia: elevated cerebrospinal fluid norepinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Impaired Presynaptic Regulation of Norepinephrine in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Clonidine treatment of schizophrenia. Double-blind comparison to placebo and neuroleptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Monoamine oxidase in schizophrenia: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

The biochemical high-risk paradigm: behavioral and familial correlates of low platelet monoamine oxidase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Brain peptides as neurotransmitters

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Naloxone-induced reversal of schizophrenic hallucinations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Intravenous Naloxone Administration in Schizophrenia and Affective Illness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Indication of an Antipsychotic Action of the Opiate Antagonist Naloxone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Effects of Naloxone on Schizophrenia: Reduction in Hallucinations in a Subpopulation of Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Naloxone as a GABA antagonist: evidence from iontophoretic, receptor binding and convulsant studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Improvement of Schizophrenic Patients Treated With Des-Tyr1]-γ-endorphin (DTγE)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Antipsychotic properties of Des-enkephalin-gamma-endorphin in treatment of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

The use of hemodialysis in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

Dialysis in schizophrenia: a double-blind evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2882%2990167-2

7 January 2021

10.1016/S0140-6736(82)90167-2

Identifiers

DOI

1 reference

16 February 2018

PubMed ID

6127468

1 reference

16 February 2018